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Abstract
Objective: Increasing evidence indicates that type 2 diabetic patients are at elevated risk for developing different
kinds of cancers. However, diabetes mellitus may be a protective factor for prostate cancer since both were found
to be negatively associated. Based on the same genetic background, parents of diabetic patients might show similar
risks concerning cancers.
Research design and methods: We conducted a case-control study, where familiy history of 794 type 2
diabetic cases and 775 non-diabetic controls was ascertained. Then, we expanded our study up to 801 type 2
diabetic cases and 1267 non-diabetic controls.
Results: Concerning the 794 type 2 diabetic patients and 775 controls, we observed that cancer of cervix uteri
was elevated among mothers of controls (odds ratio (OR) 0.19; 95% confidence interval (CI) 0.02 to 0.88; p =
0.033). Mothers of diabetic patients showed an increased history of cancers of the liver and biliary tract (OR 5.23;
95% CI 1.87 to 19.9; p = 0.0009) and stomach (OR 3.84; 95% CI 1.47 to 12.4; p = 0.0049). Pancreatic cancers
were found to be elevated in fathers of diabetic patients (OR 4.92; 95% CI 1.07 to 46.7; p = 0.039). Most notably,
a lower number of prostate cancers was observed in fathers of diabetic patients (OR 0.47; 95% CI 0.22 to 0.94;
p = 0.032). Since diabetic patients were 14.3 years older than the controls, higher levels of cancer history among
parents of diabetic patients would have been expected. Thus, the observed lower level of history of prostate
cancer can be regarded as highly reliable.
The analysis of 801 type 2 diabetics and 1267 controls showed that cancer of stomach was elevated among
mothers of controls (OR 2.67; p = 0.0106). In addition, stomach cancers were found to be elevated in fathers of
diabetic patients (OR 2.10; p = 0.0141). In accordance with the previous investigation, we again obseved a lower
number of prostate cancers in fathers of diabetic patients (OR 0.49; p = 0.0279).
However, the application of the statistical method of Mantel-Haenszel showed no significant result concerning
any of the cancer histories.
Conclusion: Fathers of patients suffering from type 2 diabetes were diagnosed less frequently with prostate
cancer compared to fathers of non-diabetic controls. As first-degree relatives, e.g. diabetic patients and their
fathers, share 50% of their genes, it appears plausible that genetic factors may play an important role in the
negative association between diabetes and prostate cancer. However, different statistic analyses showed
controversial results concerning the effect of type 2 diabetes on prostate cancers.
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Introduction
Diabetes has been associated with an increased risk of sev-
eral human malignancies, including cancers of the pan-
creas [1,2], colon [3], endometrium [4,5], breast [6],
kidney [7], liver [5,8], biliary tract [7] and esophagus [9].
However, a protective effect of diabetes mellitus on the
risk of prostate cancer has been suggested by several [4,7].
but not all studies [10,11] It has also been reported that
only long-term diabetes has a protective effect on prostate
cancer [12,13].
Recently a large, population-based cohort study in Swe-
den found a significantly decreased risk of prostate cancer
among men hospitalized for diabetes mellitus [14]. Fur-
ther evidence comes from Rosenberg et al. who reported
that white type 2 diabetic patients appear to have a lower
risk of prostate cancer [15]. However, a two hospital-
based case-control study conducted in Italy and Greece
could not confirm these findings [13].
The objective of our study was to analyze the relationship
of a diabetic genetic background and cancer. In this
report, we present results from a case-control study con-
ducted in Germany, where we ascertained the family his-
tory of cancers in type 2 diabetic patients and controls. In
our investigations, we evaluated whether paternal history
of prostate cancer was decreased among type 2 diabetic
patients.
Materials and methods
From September 2001 to February 2002, cases and con-
trols were recruited in the southern part of Germany. The
first case group consisted of 794 patients (median age
62.3 years), the second of 801 patients, who were hospi-
talised with a primary or secondary diagnosis of type 2
diabetes according to the International Classification of
Diseases (ICD-10) in the Diabetes Hospital Bad Mergen-
theim, Germany. 775 control subjects (median age 47.9
years) and 1267 controls respectively were selected from
the Center of blood donation Tuebingen, Germany. It was
required that the controls never had been diagnosed with
type 2 diabetes. This was verified by the measurement of
HbA1c, the regular check on blood glucose by the Center
of blood donation and a negative history of diabetes in
the interview.
A complete interview was obtained from all cases and
controls by two specifically trained interviewers. The
interviews were based on structured questionnaires which
included familiy history of differend kinds of cancers, e.g.
cancers of the prostate, breast, colon and rectum, uterus,
kidney, pancreas, esophagus, liver and biliary tract. All
paternal and maternal types of cancer were considered in
the statistical analysis, except data of participants being
uncertain about their parental cancer history. Since we
concentrated on the relationship of paternal prostate can-
cer and type 2 diabetes, the other cancers, which were
found to be statistically significant, must be regarded as
descriptive results. Therefore, an adjustment of p-values
for multiple testing was not done. Odds ratios, 95% con-
fidence intervals and p-values were calculated using the
statistics package JMP Version 5. In order to obtain esti-
mates of odds ratios also in tables with zero counts, we
added 0.5 to all table entries. Based on significantly differ-
ent median ages of patients and controls, terziles were
built and the effect of age on the numbers of cancers was
tested. We found that age had no influence on the num-
bers of cancers and is no biasing effect on the results.
Results
The prevalence of history of paternal and maternal cancers
and the correponding p-values, which were generated
with 794 patients and 775 controls, are shown in Table 1.
Statistically significant differences in cancer histories were
observed in both fathers and mothers of diabetic patients
and controls. These differences were found in cancers of
cervix uteri, liver and biliary tract, stomach, pancreas and
prostate.
We found a significantly increased cancer history (OR
0.19; 95% CI 0.02 to 0.88; p = 0.033) for cancer of cervix
uteri in mothers of controls (0.91%) compared with
mothers of diabetic patients (0.13%). In contrast, moth-
ers of diabetic patients showed an elevated history of can-
cer (OR 5.23; 95% CI 1.89 to 19.9; p = 0.0009) of the liver
and biliray tract (2.27 %; 0.39% in mothers of diabetic
patients and of controls, respectively). In addition, stom-
ach cancer history was also more frequent (OR 3.84; 95%
CI 1.47 to 12.4; p = 0.005) in mothers of diabetic patients
(2.14%) compared to mothers of controls (0.52 %).
Cancer history was significantly elevated (OR 4.92; 95%
CI 1.07 to 46.7; p = 0.039) in fathers of diabetic patients
concerning pancreatic cancer (0.88% compared with
0.13% in fathers of controls). Most notably, the paternal
prostate cancer history was decreased (OR 0.47; 95% CI
0.22 to 0.94; p = 0.032) among fathers of diabetic
patients. 1.39% of the fathers of the cases were reported to
suffer from prostate cancer, in contrast to 2.97% of the
fathers of the controls. There was no statistically signifi-
cant difference between the histories of other malignan-
cies in both groups.
Subsequently, the enlarged study included a total sample
of 801 type 2 diabetes patients and 1267 controls. Statis-
tically significant differencies in cancer histories, which
are presented in Table 2, were found in cancers of stomach
and prostate.Journal of Carcinogenesis 2007, 6:14 http://www.carcinogenesis.com/content/6/1/14
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Stomach cancer was significantly higher among mothers
of controls (OR 2.67; p = 0.0106) and among fathers of
diabetic patients (OR 2.10; p = 0.0141). Interestingly,
prostate cancer in fathers of type 2 diabetic patients
showed again a lower number than in fathers of controls
(OR 0.49; p = 0.0279).
However, when the Mantel-Haenszel statistics was
applied, no statistically significant results in differences
between cancer histories were observed (Table 3).
Discussion
The main findings in this case-control study conducted in
Southern Germany demonstrate that prostate cancer is
reduced in fathers of type 2 diabetic patients. In addition,
an elevated history of cancer of cervix uteri was found in
mothers of controls compared with mothers of diabetic
patients. Furthermore, the history of cancers of the liver,
biliary tract and stomach was increased in mothers of
cases. Besides, we showed that the history of pancreatic
cancer was higher in fathers of diabetic patients. On the
basis of epidemiological and biological data we had
selected prostate cancer as the main point of investigation
in our study. The observed associations of other types of
cancers with diabetes are presented as secondary results.
Therefore, an adjustment of p-values for multiple testing
was not done.
A reduced prostate cancer incidence in patients suffering
from type 2 diabetes was found in various other studies
[4,7,15] presuming the existence of a diabetes protective
effect on prostate cancer. Our data also demonstrate that
fathers of diabetic patients show a lower number of pros-
tate cancers compared to fathers of healthy controls. This
Table 1: Frequencies of cancers in parents of 794 diabetic patients and 775 controls








%%p O R%% p O R
Basalioma 0.00 0.00 0.99 0.98 0.13 0.00 0.48 2.92
Brain & other 
nervous 
system
0.63 0.39 0.53 1.54 0.25 0.26 0.97 0.97
Breast 0.00 0.00 0.99 0.98 3.65 4.15 0.61 0.88
Cervix uteri - - - - 0.13 0.91 0.033 0.19
Colon & 
rectum
1.51 2.58 0.14 0.59 2.14 2.08 0.93 1.03
Corpus uteri - - - - 3.40 1.95 0.08 1.75
Esophagus 0.13 0.26 0.60 0.58 0.13 0.00 0.48 2.92
M. Hodgkin 0.13 0.00 0.48 2.93 0.13 0.00 0.48 2.92
Kidney & 
renal pelvis
0.13 0.52 0.20 0.32 0.13 0.26 0.59 0.58
Larynx 0.50 0.52 0.97 0.98 0.25 0.00 0.24 4.87
Leukemia 0.13 0.13 0.98 0.98 0.76 0.78 0.96 0.97
Liver & biliary 
tract
1.01 1.16 0.77 0.87 2.27 0.39 0.0009 5.23
Lung & 
bronchus
2.52 2.71 0.81 0.93 0.76 0.52 0.58 1.41
Melanoma 0.00 0.26 0.22 0.19 0.38 0.26 0.71 1.36
NHL 0.00 0.00 0.99 0.98 0.00 0.13 0.46 0.32
Oral cavity & 
pharynx
0.50 0.52 0.97 0.98 0.00 0.00 0.99 0.98
Ovary - - - - 0.38 0.26 0.71 1.36
Pancreas 0.88 0.13 0.039 4.92 0.25 1.04 0.056 0.28
Prostate 1.39 2.97 0.032 0 . 4 7-- --
Stomach 3.15 1.94 0.13 1.63 2.14 0.52 0.005 3.84
Testis 0.38 0.26 0.70 1.37 - - - -
Thyroid 0.00 0.13 0.46 0.32 0.25 0.00 0.24 4.87
Urinary 
bladder
0.13 0.52 0.20 0.32 0.25 0.00 0.24 4.87
p-values < 0.05 are typed in bold letters; in order to estimate odds ratios (OR) even in the presence of zero counts the value of 0.5 was added to 
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lower history of prostate cancer in fathers of diabetic
patients can be connected with common ways of nutrition
as well as shared genetic factors since first grade relatives
have 50% of their genes in common. Thus, our findings
confirm the hypothesis of a diabetes protective effect on
prostate cancer and emphasise the important role of
genetic factors in this progress. Since the median age of
the case group was substantial higher than the median age
of the controls, fathers of diabetic patients even had a
higher possibility of developing prostate cancer as its inci-
dence rises by age. Therefore, the observed reduction of
paternal prostate cancer is unlikely to be due to bias on
the different median ages of the case and control groups.
This protective role of diabetes on prostate cancer may be
explained in terms of decreased levels of insulin-like
growth factor I (IGF-I) which have been reported in dia-
betic patients with hyperinsulinemia by some studies [16-
19] In addition, chronic hyperinsulinemia was found to
be inversely associated with plasma testosterone levels
[20]. Clinical and epidemiological observations suggest
that both IGF-I and androgens may enhance prostate
tumour development [20-22]. In view of the alterations in
serum testosterone and IGF-I concentrations caused by
diabetes mellitus, a reduction of prostate cancer risk
among humans with a genetic background of diabetes
appears biologically plausible [16].
Another possible explanation for the diabetes protective
effect on prostate cancer could be the existence of a genetic
factor that on one hand raises the risk of diabetes while on
the other hand lowering the prostate cancer risk. Genetic
variation in PPAR-gamma (MIM# 601487) e.g. was found
to be associated with a higher incidence of diabetes melli-
tus [23,24] In addition, PPAR-gamma was shown to be
expressed in human prostate adenocarcinomas and
derived cell lines. Moreover, the activation of this receptor
with specific ligands leads to an inhibition of prostate can-
cer cell growth [25].
In conclusion, we report for the first time that fathers of
type 2 diabetic patients show decreased history of prostate
cancer. A protective effect of diabetes predisposing genetic




Table 3: Frequencies of cancers in parents of 801 diabetic patients 
and 1267 controls (Mantel-Haenszel statistics)








% % OR % % OR
Basalioma 0.00 0.00 1.71 0.12 0.00 1.92
Breast 0.00 0.08 1.48 3.62 3.95 0.95
Colon & 
rectum
1.50 2.05 0.81 2.12 2.13 0.95
Leukemia 0.12 0.39 0.87 0.75 0.55 1.24
Lung & 
bronchus
2.50 2.53 0.88 0.75 0.71 0.81




0.00 0.00 1.71 0.00 0.16 1.30
Prostate 1.37 2.84 0.61 - - -
Stomach 3.12 1.50 1.77 2.12 0.79 1.68
Table 2: Frequencies of cancers in parents of 801 diabetic patients and 1267 controls
Fathers of Mothers of





%%p O R%%p O R
Basalioma 0.00 0.00 0.82 1.58 0.12 0.00 0.30 4.75
Breast 0.00 0.08 0.68 0.53 3.62 3.95 0.73 0.92
Colon & rectum 1.50 2.05 0.38 0.74 2.12 2.13 0.98 1.01
Leukemia 0.12 0.39 0.33 0.43 0.75 0.55 0.56 1.37
Lung & bronchus 2.50 2.53 0.99 1.00 0.75 0.71 0.88 1.08
Melanoma 0.00 0.32 0.15 0.18 0.37 0.16 0.33 2.22
Non-Hodkin-
Lymphoma
0.00 0.00 0.82 1.58 0.00 0.16 0.40 0.32
Prostate 1.37 2.84 0.03 0 . 4 9----
Stomach 3.12 1.50 0.01 2.10 2.12 0.79 0.01 2.67
p-values < 0.05 are typed in bold letters; in order to estimate odds ratios (OR) even in the presence of zero counts the value of 0.5 was added to 
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IGF-1 (insulin-like growth factor I)
OR (odds ratio)
PPAR-gamma (peroxisome proliferator-activated recep-
tor-gamma)
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